Summit Appoints Robert W. Duggan as Executive Chairman
February 26 2020 - 6:00AM
Summit Therapeutics plc (‘Summit’ or the
‘Company’)
Summit Appoints Robert W. Duggan as Executive
Chairman
Oxford, UK, and Cambridge, MA, US, 26
February 2020 – Summit Therapeutics plc (NASDAQ: SMMT)
today announces it has appointed Robert W. Duggan as Executive
Chairman of the Board of Directors with immediate effect. Glyn
Edwards will continue as an Executive Director and Chief Executive
Officer.
“Mr Duggan has a track record of building
successful commercial organisations aimed at bettering people’s
lives,” said Mr Glyn Edwards, Chief Executive Officer of
Summit. “We believe his guidance will help us ensure our
targeted antibiotic product candidate ridinilazole has the best
opportunity to reach patients with C. difficile infection who
desperately need novel treatment options.”
“Targeted antibiotics have the potential to
improve the way infectious diseases are treated by targeting the
infectious bacteria and minimising the damage of the healthy and
protective microbiome. In C. difficile infection, the selective
targeting of the infectious bacteria has significant potential to
reduce recurrence and improve patient outcomes,” commented
Mr Robert W. Duggan. “I look forward to being part of the
Summit team to realise the full potential of these medicines in
bettering patients’ lives.”
About Robert W. DugganMr Robert
W. Duggan is a serial US based entrepreneur who has built several
successful companies across different industries, including
biotechnology. Mr Duggan is currently the Chief Executive Officer
of Duggan Investment Inc., a private US investment firm, and a
member of the board of directors of Summit. Mr Duggan has served on
the boards of a number of US public and private companies and he is
currently chairman of the board of the Nasdaq listed company, Pulse
Biosciences, Inc. He was previously a substantial shareholder in
and the Chairman of the Board and Chief Executive Officer of
Pharmacyclics, Inc., which was sold to AbbVie Inc. in 2015.
Previously, he was the Chairman of the Board and Chief Executive
Officer of Computer Motion, Inc., which later merged with Intuitive
Surgical, Inc.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of
care for the benefit of patients and create value for payors and
healthcare providers. We are currently developing new mechanism
antibiotics for infections caused by C. difficile,
Enterobacteriaceae and N. gonorrhoeae and are using our proprietary
Discuva Platform to expand our pipeline. For more information,
visit www.summitplc.com and follow us on Twitter @summitplc.
Contacts
Summit |
|
|
Glyn Edwards / Richard Pye (UK office) |
Tel: |
44 (0)1235 443 951 |
Michelle Avery (US office) |
|
+1 617 225 4455 |
|
|
|
MSL Group (US media) |
Tel: |
+1 781 684 6552 |
Erin Anthoine |
|
summit@mslgroup.com |
|
|
|
Consilium Strategic Communications (UK media) |
Tel: |
+44 (0)20 3709 5700 |
Mary-Jane Elliott / Sue Stuart / Sukaina Virji |
|
summit@consilium-comms.com |
Lindsey Neville |
|
|
Summit Forward-looking Statements
Any statements in this press release about the
Company’s future expectations, plans and prospects, including but
not limited to, statements about the clinical and preclinical
development of the Company’s product candidates, the therapeutic
potential of the Company’s product candidates, the potential
commercialisation of the Company’s product candidates, the
sufficiency of the Company’s cash resources, the timing of
initiation, completion and availability of data from clinical
trials, the potential submission of applications for marketing
approvals and other statements containing the words "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intend,"
"may," "plan," "potential," "predict," "project," "should,"
"target," "would," and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties inherent in the initiation of future clinical trials,
availability and timing of data from ongoing and future clinical
trials and the results of such trials, whether preliminary results
from a clinical trial will be predictive of the final results of
that trial or whether results of early clinical trials or
preclinical studies will be indicative of the results of later
clinical trials, expectations for regulatory approvals, laws and
regulations affecting government contracts and funding awards,
availability of funding sufficient for the Company’s foreseeable
and unforeseeable operating expenses and capital expenditure
requirements and other factors discussed in the "Risk Factors"
section of filings that the Company makes with the Securities and
Exchange Commission, including the Company’s Annual Report on Form
20-F for the fiscal year ended 31 January 2019. Accordingly,
readers should not place undue reliance on forward-looking
statements or information. In addition, any forward-looking
statements included in this press release represent the Company’s
views only as of the date of this release and should not be relied
upon as representing the Company’s views as of any subsequent date.
The Company specifically disclaims any obligation to update any
forward-looking statements included in this press release.
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024